Drug intelligence / Profile preview

INV-201

Development stage: Unknown
Lead developer: Invizius
Modality: Recombinant Proteins and Enzymes

Overview

INV-201 is a protein drug under development by Invizius Ltd. It is being investigated for the treatment of peritoneal fibrosis, a condition associated with digestive system disorders. The drug is currently in the discovery phase and has not yet entered clinical trials. Specific details regarding its mechanism of action, molecular target, or additional pharmacological properties have not been disclosed publicly as of June 2025[1].

Brand names: Meso-Guard
Other names: INV-201INV201INV 201

Targets

C3 convertase (Ficolin-3)

Beyond the preview

Go deeper on INV-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INV-201.

Explore the full profile